. However, these develop¬ ments have overshadowed persistent reports in the literature that a factor or factors are able to inhibit
originally demonstrated in the dog that if the pituitary was disconnected from the hypothalamus, there remained a high basal level of corticosteroids, and that this was not due to any brain-stem stimulatory factor (Egdahl, 1962 (Halasz, Vernikos-Danellis & Gorski, 1967 In their study of hypothalamic-releasing factors, Gillies, Puri, Linton & Lowry (1984) showed by gel chromatography two principal peaks of ACTHreleasing activity, which corresponded to CRF-41 and vasopressin, as well as at least one further peak required for full activity. However, they also noted the presence of ACTH-inhibitory activity in their Bio-Gel (but not Sephadex) chromatograms of a molecular weight intermediate between CRF-41 and vaso¬ pressin. Redei & Evans (1987) have further identified this factor as a peptide of probable molecular weight 0-6-2-3 kDa, but have not so far published a sequence analysis.
The other approach, that of systematically investi¬ gating putative agents for CIA, has also been actively explored. Somatostatin is widely inhibitory to a variety of hormones and, in the rat, somatostatin-14 was found to inhibit ACTH release at high concen¬ trations directly (Nicholson, Adrian, Gillham et al. 1984) . However, no effect on cultured pituitary cells was shown by Brown, Rivier & Vale (1984) (Antoni, Holmes & Jones, 1983) , while immunoneutralization leads to a fall in ACTH (Gibbs, 1985) . The significance of the human studies therefore remains uncertain. Substance was found to inhibit the release of ACTH from pituitary cells in vitro (Nicholson et al. 1984 ), and it is thus possible that this peptide or one of its tachykinin congeners is important in ACTH inhibitory regulation, but the effect is weak and has not been confirmed in a more recent study employing freshly dispersed pituitary cells (Chowdrey, Jessop & Lightman, 1989) . GABA is another neurotransmitter that appears to be involved in the neuroregulation of ACTH; while increasing GABA bioavailability has no effect on the pituitaryadrenal axis under basal conditions (Abraham, Dornhorst, Wynn et al. 1985) , such pharmacological manipulation appears to inhibit the response of the axis to hypoglycaemia (Petraglia, Bakalakis, Facchinetti et al. 1986 ). However, in spite of the presence of GABA receptors within the pituitary, GABA does not appear to inhibit pituitary ACTH release directly (Hashimoto, Yunoki, Takahara & Ofuji, 1979; Anderson & Mitchell, 1986) , and most evidence suggests that GABA acts within the hypo¬ thalamus to inhibit the release of CRF bioactivity (Jones, Hillhouse & Burden, 1976) (Plotsky, 1986) , while morphine suppresses the secretion of CRF-41 from rat hypo¬ thalamic expiants in vitro (Tsagarakis, Navara, Rees et al. 1989 ). As similar opiates stimulate CRF bio¬ activity in vitro (Buckingham, 1982) , it is possible that the resultant biological effect is due to inhibition of both CRF-41 and a corticotrophin-inhibitory factor, the latter influence being predominant in short-term studies (Cover & Buckingham, 1989; Tsagarakis et al. 1989 ). In man, in whom opiates only inhibit ACTH, this disinhibitory control is not seen, and modulation most probably occurs via changes in CRF-41 and vasopressin alone.
Most recently, another candidate peptide has received increasing scrutiny. Atrial natriuretic peptide (ANP) has profound effects on salt balance and vascu¬ lar tone, and also inhibits aldosterone and renin release (Anderson & Bloom, 1986) . While one study reported that ANP(4-28) inhibited pituitary ACTH release (Shibasaki, Naruse, Yamauchi et al. 1986ft ), this was not confirmed in several later investigations (Heisler, Simard, Assayag et al. 1986 ; Abou-Samra, Catt & Aguilera, 1987; Hashimoto, Hattori, Suemaru et al. 1987 ). However, Antoni & Dayanithi (1989) (Dayanithi & Antoni, 1990; King & Baertschi, 1989 (Quirion, Dalpe, De Lean et al. 1984) and ANP mRNA is present in the hypothalamus (Standaert, Needleman, Day et al. 1988) ; furthermore, ANP release may be stimulated by potassium depolariza¬ tion from the rat hypothalamus in vitro (Shibasaki, Naruse, Naruse et al. 1986 ). Thus, the stage is set for further exploration of its role as a physiologically important corticotrophin-inhibitory factor, particu¬ larly in terms of changes in ACTH in response to blood volume homeostasis.
Finally, there is a recent suggestion that the mammalian homologue of melanin-concentrating hormone contains a weak ACTH-inhibitory factor in its precursor peptide (Presse, Nahon, Sawchenko & Vale, 1989) . However, it is still too early to judge whether this is a physiological as opposed to a pharmacological function.
Thus both investigatory stratagems have postulated peptides with CIA, the first a novel 10-20 residue pep¬ tide, the second a series of possibilities, including ANP or its central nervous system derivative and other completely original structures. Certainly, the linking of cGMP to inhibition of ACTH release is strong presumptive evidence in favour of an endogen¬ ous inhibitory factor. Clearly it is also possible that the peptide described by Redei & Evans (1987) is identical to one of the putative peptides with CIA, and it would be extremely interesting to know whether immunoneutralization with antiserum to oxytocin or ANP is able to abolish the biological activity of this peptide. Further studies are awaited with interest, particularly with regard to the effects of ANP in man.
